title: Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and siRNA screening applications.
abstract: Sensitization of adenylyl cyclase (AC) signaling has been implicated in a variety of neuropsychiatric and neurologic disorders including substance abuse and Parkinson's disease. Acute activation of Gαi/o-linked receptors inhibits AC activity, whereas persistent activation of these receptors results in heterologous sensitization of AC and increased levels of intracellular cAMP. Previous studies have demonstrated that this enhancement of AC responsiveness is observed both in vitro and in vivo following the chronic activation of several types of Gαi/o-linked receptors including D2 dopamine and μ opioid receptors. Although heterologous sensitization of AC was first reported four decades ago, the mechanism(s) that underlie this phenomenon remain largely unknown. The lack of mechanistic data presumably reflects the complexity involved with this adaptive response, suggesting that nonbiased approaches could aid in identifying the molecular pathways involved in heterologous sensitization of AC. Previous studies have implicated kinase and Gbγ signaling as overlapping components that regulate the heterologous sensitization of AC. To identify unique and additional overlapping targets associated with sensitization of AC, the development and validation of a scalable cAMP sensitization assay is required for greater throughput. Previous approaches to study sensitization are generally cumbersome involving continuous cell culture maintenance as well as a complex methodology for measuring cAMP accumulation that involves multiple wash steps. Thus, the development of a robust cell-based assay that can be used for high throughput screening (HTS) in a 384 well format would facilitate future studies. Using two D2 dopamine receptor cellular models (i.e. CHO-D2L and HEK-AC6/D2L), we have converted our 48-well sensitization assay (>20 steps 4-5 days) to a five-step, single day assay in 384-well format. This new format is amenable to small molecule screening, and we demonstrate that this assay design can also be readily used for reverse transfection of siRNA in anticipation of targeted siRNA library screening.
authors: Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University.
authors: Jason M
authors: JM
authors: Conley
authors: Tarsis F
authors: TF
authors: Brust
authors: Ruqiang
authors: R
authors: Xu
authors: Kevin D
authors: KD
authors: Burris
authors: Val J
authors: VJ
authors: Watts
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D016466:CHO Cells; D003412:Cricetulus; D000242:Cyclic AMP / Q000378:metabolism; D057809:HEK293 Cells; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D008904:Miniaturization / Q000379:methods; D034741:RNA, Small Interfering / Q000032:analysis* / Q000235:genetics; D051381:Rats; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D054852:Small Molecule Libraries / Q000032:analysis* / Q000494:pharmacology*; D014162:Transfection
chemical_list: D034741:RNA, Small Interfering; D017448:Receptors, Dopamine D2; D054852:Small Molecule Libraries; D000242:Cyclic AMP; D000262:Adenylyl Cyclases